Pyrazolopyrrolidine Compounds Inhibit MDM2-p53 Interaction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for proliferative diseases, such as cancer, lack effective drugs that can inhibit the interaction between p53 and MDM2 or MDM4, allowing p53 to exert its tumor suppressor functions and prevent uncontrolled cell proliferation.
Innovation Solution
Development of novel pyrazolopyrrolidine compounds that specifically inhibit the interaction between p53 and MDM2 or MDM4, demonstrating potent inhibition in assays and favorable pharmacokinetic properties, stability, and low toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for proliferative diseases are used, then existing therapeutic options are available, but they cannot effectively inhibit the interaction between p53 and MDM2/MDM4
Solution Approach 1:
The patent develops novel pyrazolopyrrolidine compounds with specific chemical structures (formula I) that change the molecular parameters to enable effective binding to MDM2/MDM4. The compounds feature specific substituents (R1-R8, A, B) that optimize the interaction with the target proteins, achieving potent inhibition of the p53-MDM2 axis that current treatments cannot accomplish.
2Reliability
If potent inhibitors of p53-MDM2 interaction are developed, then tumor suppressor function is restored, but drug toxicity and stability issues may arise
Solution Approach 1:
The pyrazolopyrrolidine compounds act as intermediary molecules that specifically bind to MDM2/MDM4, preventing these proteins from interacting with p53. This intermediary approach allows restoration of p53 tumor suppressor function without directly modifying p53 itself, potentially reducing off-target effects and toxicity while maintaining therapeutic efficacy.
3Productivity
If new drug compounds are developed to inhibit MDM2/p53 interaction, then therapeutic efficacy is improved, but formulation and stability challenges increase
Solution Approach 1:
The patent optimizes specific local regions of the pyrazolopyrrolidine molecule (substituents at different positions on the core structure) to achieve the right balance between biological activity and pharmaceutical properties. By carefully selecting and positioning specific functional groups (R1-R8, A, B), the compounds attain both potent MDM2 inhibition and improved stability/formulability characteristics.
Data Source
AI summary
The invention relates to compounds of formula (I) as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.